Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

14.89 +0.30 (+2.06%)
Streaming Delayed Price Updated: 9:32 AM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
Earnings Scheduled For November 2, 2021 ↗
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
News headline image
Earnings Outlook For Regenxbio ↗
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
News headline image
Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial ↗
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
News headline image
44 Biggest Movers From Yesterday ↗
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5... 
Via Benzinga
News headline image
30 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
News headline image
Could AbbVie's New Collaboration Be a Blockbuster? ↗
AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment. 
Via The Motley Fool
News headline image
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal ↗
The big drugmaker wants another near-term growth driver. 
Via The Motley Fool
News headline image
Looking Into Regenxbio's Return On Capital Employed ↗
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.04 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 18.58%, resulting in a loss of $... 
Via Benzinga
News headline image
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal ↗
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector. 
Via Talk Markets
News headline image
Regenxbio Stock Catapults To 7-Month High On AbbVie's $1.75 Billion Bet On Gene Therapy ↗
Regenxbio stock rocketed Monday after the company announced an AbbVie eye-disease deal. At one point, RGNX stock hit a seven-month high. 
Via Investor's Business Daily
News headline image
Why Regenxbio Stock Is Way Up Today ↗
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration. 
Via The Motley Fool
News headline image
72 Biggest Movers From Yesterday ↗
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Itamar Medical (NASDAQ:ITMR) shares increased by 46.58% to $30.25 during Monday's regular session. Trading volume for Itamar Medical's stock is 2.6 million... 
Via Benzinga
News headline image
45 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)... 
Via Benzinga
News headline image
Why Regenxbio Shares Are Trading Higher Today ↗
Regenxbio Inc (NASDAQ: RGNX) is trading significantly higher Monday after the company, and AbbVie Inc (NYSE: ABBV), announced an eye care collaboration. The companies will develop... 
Via Benzinga
News headline image
AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration ↗
AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Itamar Medical (NASDAQ:ITMR) shares moved upwards by 44.37% to $29.8 during Monday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
News headline image
REGENXBIO inc (RGNX) Q2 2021 Earnings Call Transcript ↗
RGNX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the... 
Via Talk Markets
News headline image
18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... 
Via Benzinga
News headline image
Earnings Scheduled For August 9, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
News headline image
Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years ↗
Regenxbio Inc (NASDAQ: RGNX) has announced a safety update and additional positive interim data from its ongoing Phase 1/2 trial of RGX-121 to treat patients... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.